IL172035A0 - Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window - Google Patents

Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window

Info

Publication number
IL172035A0
IL172035A0 IL172035A IL17203505A IL172035A0 IL 172035 A0 IL172035 A0 IL 172035A0 IL 172035 A IL172035 A IL 172035A IL 17203505 A IL17203505 A IL 17203505A IL 172035 A0 IL172035 A0 IL 172035A0
Authority
IL
Israel
Prior art keywords
restoration
organs
enhancement
tissues
protection
Prior art date
Application number
IL172035A
Other languages
English (en)
Original Assignee
Kenneth S Warren Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth S Warren Inst Inc filed Critical Kenneth S Warren Inst Inc
Publication of IL172035A0 publication Critical patent/IL172035A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
IL172035A 2003-05-19 2005-11-17 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window IL172035A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47166103P 2003-05-19 2003-05-19
PCT/US2004/015733 WO2004112693A2 (en) 2003-05-19 2004-05-19 Tissue protective cytokines with an extended therapeutic window

Publications (1)

Publication Number Publication Date
IL172035A0 true IL172035A0 (en) 2009-02-11

Family

ID=33539032

Family Applications (1)

Application Number Title Priority Date Filing Date
IL172035A IL172035A0 (en) 2003-05-19 2005-11-17 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window

Country Status (13)

Country Link
US (1) US20090258821A1 (enExample)
EP (1) EP1633305A2 (enExample)
JP (1) JP2007505159A (enExample)
KR (1) KR20060013547A (enExample)
CN (1) CN1946416A (enExample)
BR (1) BRPI0410470A (enExample)
CA (1) CA2526096A1 (enExample)
EA (1) EA200501828A1 (enExample)
IL (1) IL172035A0 (enExample)
IS (1) IS8156A (enExample)
MX (1) MXPA05012515A (enExample)
NO (1) NO20056000L (enExample)
WO (1) WO2004112693A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
JP2006521405A (ja) * 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 発作回復におけるエリトロポイエチンの使用
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
JP2008505184A (ja) * 2004-07-02 2008-02-21 ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド 完全にカルバミル化されたエリトロポイエチンを生成する方法
EP1781697B1 (en) * 2004-07-07 2009-04-22 H.Lundbeck A/S Novel carbamylated epo and method for its production
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
TW201129374A (en) * 2009-10-26 2011-09-01 Lundbeck & Co As H Use of carbamylated erythropoietin for the treatment of Friedreich's ataxia
US9956265B2 (en) * 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
HRP20220519T1 (hr) * 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US10695402B2 (en) * 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
RU2762892C1 (ru) * 2021-02-18 2021-12-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляторных нарушений сетчатки асиалированным эритропоэтином

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
JP2006521405A (ja) * 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 発作回復におけるエリトロポイエチンの使用

Also Published As

Publication number Publication date
MXPA05012515A (es) 2006-05-25
US20090258821A1 (en) 2009-10-15
WO2004112693A2 (en) 2004-12-29
IS8156A (is) 2005-11-29
CN1946416A (zh) 2007-04-11
WO2004112693A3 (en) 2006-06-29
KR20060013547A (ko) 2006-02-10
CA2526096A1 (en) 2004-12-29
JP2007505159A (ja) 2007-03-08
EA200501828A1 (ru) 2006-08-25
EP1633305A2 (en) 2006-03-15
BRPI0410470A (pt) 2006-06-20
NO20056000L (no) 2006-02-20

Similar Documents

Publication Publication Date Title
EP1575528A4 (en) TREATMENT PROTECTIVE CYTOKINS FOR THE PROTECTION, RECOVERY AND STRENGTHENING OF RESPECTIVE CELLS, TISSUE AND ORGANS
PL374580A1 (en) Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
IL156399A0 (en) Protection, restoration, and enhancement of erythropoietein-responsive cells, tissues and organs
IL171501A (en) Genetically engineered cutaneous microorganisms and their use
WO2006003094A3 (en) Merocyanine derivatives
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
AU2003226321A1 (en) Distal protection double balloon catheter
IL175462A0 (en) Ocular surgical protective shield
AU2003229923A1 (en) Curcumin for the prevention and/or treatment of tissue damage
IL166475A (en) Use of glutamine or carbohydrate to prepare the composition for the purpose of protecting non-mucosal tissues against damage caused by radiation therapy
AU2002952993A0 (en) Therapeutic and diagnostic agents
AU2003261860A1 (en) Composition for protecting organ, tissue or cell and utilization thereof
IS8156A (is) Vefjaverndandi frumuboðar til þess að vernda, endurheimta og bæta svarbúnar frumur, vefi og líffæri, og hafa lengda meðferðargetu
AU2003276129A1 (en) Compositions and methods for darkening the skin
AU2003300435A8 (en) Tissue and organ preservation, protection and resuscitation
AU2003288971A1 (en) Compositions for darkening the skin and/or hair
AU2003215078A1 (en) Prevention of transgene escape in genetically modified perennials
IL176027A0 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
IL172036A0 (en) Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window
AU2003275610A1 (en) Liquid skin protective composition
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2003288972A1 (en) Compositions for darkening the skin and/or hair
AU2003904303A0 (en) Nerve function and tissue healing
WO2005084364A3 (en) Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AU2003235665A1 (en) Diagnostic and therapeutic uses of topors